title
stringlengths 1
251
| section
stringlengths 0
6.12k
| text
stringlengths 0
716k
|
|---|---|---|
Aspirin | Polymorphism | Polymorphism
Polymorphism is the ability of a substance to form more than one crystal structure. Until 2005, there was only one proven polymorph of aspirin (form I), though the existence of another polymorph was debated since the 1960s, and one report from 1981 reported that when crystallized in the presence of aspirin anhydride, the diffractogram of aspirin has weak additional peaks. Though at the time it was dismissed as mere impurity, it was, in retrospect, form II aspirin.
Form II was reported in 2005, found after attempted co-crystallization of aspirin and levetiracetam from hot acetonitrile. Pure form II aspirin can be prepared by seeding the batch with aspirin anhydrate in 15% weight.
In form I, pairs of aspirin molecules form centrosymmetric dimers through the acetyl groups with the (acidic) methyl proton to carbonyl hydrogen bonds. In form II, each aspirin molecule forms the same hydrogen bonds, but with two neighbouring molecules instead of one. With respect to the hydrogen bonds formed by the carboxylic acid groups, both polymorphs form identical dimer structures. The aspirin polymorphs contain identical 2-dimensional sections and are therefore more precisely described as polytypes.
Form III was reported in 2015 by compressing Form I above 2 GPa, but it reverts to form I when pressure is removed. Form IV was reported in 2017, which is stable at ambient conditions. |
Aspirin | Mechanism of action | Mechanism of action |
Aspirin | Discovery of the mechanism | Discovery of the mechanism
In 1971, British pharmacologist John Robert Vane, then employed by the Royal College of Surgeons in London, showed that aspirin suppressed the production of prostaglandins and thromboxanes. For this discovery, he was awarded the 1982 Nobel Prize in Physiology or Medicine, jointly with Sune Bergström and Bengt Ingemar Samuelsson. |
Aspirin | Prostaglandins and thromboxanes | Prostaglandins and thromboxanes
Aspirin's ability to suppress the production of prostaglandins and thromboxanes is due to its irreversible inactivation of the cyclooxygenase (COX; officially known as prostaglandin-endoperoxide synthase, PTGS) enzyme required for prostaglandin and thromboxane synthesis. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a serine residue in the active site of the COX enzyme (suicide inhibition). This makes aspirin different from other NSAIDs (such as diclofenac and ibuprofen), which are reversible inhibitors.
Low-dose aspirin use irreversibly blocks the formation of thromboxane A2 in platelets, which inhibits platelet aggregation during the lifetime of the affected platelet (8–9 days). This antithrombotic property makes aspirin useful for reducing the incidence of heart attacks in people who have had a heart attack, unstable angina, ischemic stroke or transient ischemic attack. 40mg of aspirin a day is able to inhibit a large proportion of maximum thromboxane A2 release provoked acutely, with the prostaglandin I2 synthesis being little affected; however, higher doses of aspirin are required to attain further inhibition.
Prostaglandins, a type of hormone, have diverse effects, including the transmission of pain information to the brain, modulation of the hypothalamic thermostat, and inflammation. Thromboxanes are responsible for the aggregation of platelets that form blood clots. Heart attacks are caused primarily by blood clots, and low doses of aspirin are seen as an effective medical intervention to prevent a second acute myocardial infarction. |
Aspirin | COX-1 and COX-2 inhibition | COX-1 and COX-2 inhibition
At least two different types of cyclooxygenases, COX-1 and COX-2, are acted on by aspirin. Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory. Aspirin-modified COX-2 (aka prostaglandin-endoperoxide synthase 2 or PTGS2) produces epi-lipoxins, most of which are anti-inflammatory. Newer NSAID drugs, COX-2 inhibitors (coxibs), have been developed to inhibit only COX-2, with the intent to reduce the incidence of gastrointestinal side effects.
Several COX-2 inhibitors, such as rofecoxib (Vioxx), have been withdrawn from the market, after evidence emerged that COX-2 inhibitors increase the risk of heart attack and stroke. Endothelial cells lining the microvasculature in the body are proposed to express COX-2, and, by selectively inhibiting COX-2, prostaglandin production (specifically, PGI2; prostacyclin) is downregulated with respect to thromboxane levels, as COX-1 in platelets is unaffected. Thus, the protective anticoagulative effect of PGI2 is removed, increasing the risk of thrombus and associated heart attacks and other circulatory problems.
Furthermore, aspirin, while inhibiting the ability of COX-2 to form pro-inflammatory products such as the prostaglandins, converts this enzyme's activity from a prostaglandin-forming cyclooxygenase to a lipoxygenase-like enzyme: aspirin-treated COX-2 metabolizes a variety of polyunsaturated fatty acids to hydroperoxy products which are then further metabolized to specialized proresolving mediators such as the aspirin-triggered lipoxins(15-epilipoxin-A4/B4), aspirin-triggered resolvins, and aspirin-triggered maresins. These mediators possess potent anti-inflammatory activity. It is proposed that this aspirin-triggered transition of COX-2 from cyclooxygenase to lipoxygenase activity and the consequential formation of specialized proresolving mediators contributes to the anti-inflammatory effects of aspirin. |
Aspirin | Additional mechanisms | Additional mechanisms
Aspirin has been shown to have at least three additional modes of action. It uncouples oxidative phosphorylation in cartilaginous (and hepatic) mitochondria, by diffusing from the inner membrane space as a proton carrier back into the mitochondrial matrix, where it ionizes once again to release protons. Aspirin buffers and transports the protons. When high doses are given, it may actually cause fever, owing to the heat released from the electron transport chain, as opposed to the antipyretic action of aspirin seen with lower doses. In addition, aspirin induces the formation of NO-radicals in the body, which have been shown in mice to have an independent mechanism of reducing inflammation. This reduced leukocyte adhesion is an important step in the immune response to infection; however, evidence is insufficient to show that aspirin helps to fight infection. More recent data also suggest salicylic acid and its derivatives modulate signalling through NF-κB. NF-κB, a transcription factor complex, plays a central role in many biological processes, including inflammation.
Aspirin is readily broken down in the body to salicylic acid, which itself has anti-inflammatory, antipyretic, and analgesic effects. In 2012, salicylic acid was found to activate AMP-activated protein kinase, which has been suggested as a possible explanation for some of the effects of both salicylic acid and aspirin. The acetyl portion of the aspirin molecule has its own targets. Acetylation of cellular proteins is a well-established phenomenon in the regulation of protein function at the post-translational level. Aspirin is able to acetylate several other targets in addition to COX isoenzymes. These acetylation reactions may explain many hitherto unexplained effects of aspirin. |
Aspirin | Formulations | Formulations
Aspirin is produced in many formulations, with some differences in effect. In particular, aspirin can cause gastrointestinal bleeding, and formulations are sought which deliver the benefits of aspirin while mitigating harmful bleeding. Formulations may be combined (e.g., buffered + vitamin C).
Tablets, typically of about 75–100 mg and 300–320 mg of immediate-release aspirin (IR-ASA).
Dispersible tablets.
Enteric-coated tablets.
Buffered formulations containing aspirin with one of many buffering agents.
Formulations of aspirin with vitamin C (ASA-VitC)
A phospholipid-aspirin complex liquid formulation, PL-ASA. , the phospholipid coating is being trialled to determine if it causes less gastrointestinal damage. |
Aspirin | Pharmacokinetics | Pharmacokinetics
Acetylsalicylic acid is a weak acid, and very little of it is ionized in the stomach after oral administration. Acetylsalicylic acid is quickly absorbed through the cell membrane in the acidic conditions of the stomach. The higher pH and larger surface area of the small intestine cause aspirin to be absorbed more slowly there, as more of it is ionized. Owing to the formation of concretions, aspirin is absorbed much more slowly during overdose, and blood plasma concentrations can continue to rise for up to 24 hours after ingestion.
About 50–80% of salicylate in the blood is bound to human serum albumin, while the rest remains in the active, ionized state; protein binding is concentration-dependent. Saturation of binding sites leads to more free salicylate and increased toxicity. The volume of distribution is 0.1–0.2 L/kg. Acidosis increases the volume of distribution because of enhancement of tissue penetration of salicylates.
As much as 80% of therapeutic doses of salicylic acid is metabolized in the liver. Conjugation with glycine forms salicyluric acid, and with glucuronic acid to form two different glucuronide esters. The conjugate with the acetyl group intact is referred to as the acyl glucuronide; the deacetylated conjugate is the phenolic glucuronide. These metabolic pathways have only a limited capacity. Small amounts of salicylic acid are also hydroxylated to gentisic acid. With large salicylate doses, the kinetics switch from first-order to zero-order, as metabolic pathways become saturated and renal excretion becomes increasingly important.
Salicylates are excreted mainly by the kidneys as salicyluric acid (75%), free salicylic acid (10%), salicylic phenol (10%), acyl glucuronides (5%), gentisic acid (< 1%), and 2,3-dihydroxybenzoic acid. When small doses (less than 250mg in an adult) are ingested, all pathways proceed by first-order kinetics, with an elimination half-life of about 2.0 h to 4.5 h. When higher doses of salicylate are ingested (more than 4 g), the half-life becomes much longer (15 h to 30 h), because the biotransformation pathways concerned with the formation of salicyluric acid and salicyl phenolic glucuronide become saturated. Renal excretion of salicylic acid becomes increasingly important as the metabolic pathways become saturated, because it is extremely sensitive to changes in urinary pH. A 10- to 20-fold increase in renal clearance occurs when urine pH is increased from 5 to 8. The use of urinary alkalinization exploits this particular aspect of salicylate elimination. It was found that short-term aspirin use in therapeutic doses might precipitate reversible acute kidney injury when the patient was ill with glomerulonephritis or cirrhosis. Aspirin for some patients with chronic kidney disease and some children with congestive heart failure was contraindicated. |
Aspirin | History | History
thumb|left|1923 advertisement
Medicines made from willow and other salicylate-rich plants appear in clay tablets from ancient Sumer as well as the Ebers Papyrus from ancient Egypt. Hippocrates referred to the use of salicylic tea to reduce fevers around 400 BC, and willow bark preparations were part of the pharmacopoeia of Western medicine in classical antiquity and the Middle Ages. Willow bark extract became recognized for its specific effects on fever, pain, and inflammation in the mid-eighteenth century after the Rev Edward Stone of Chipping Norton, Oxfordshire, noticed that the bitter taste of willow bark resembled the taste of the bark of the cinchona tree, known as "Peruvian bark", which was used successfully in Peru to treat a variety of ailments. Stone experimented with preparations of powdered willow bark on people in Chipping Norton for five years and found it to be as effective as Peruvian bark and a cheaper domestic version. In 1763, he sent a report of his findings to the Royal Society in London. By the nineteenth century, pharmacists were experimenting with and prescribing a variety of chemicals related to salicylic acid, the active component of willow extract.
thumb|Old package. "Export from Germany is prohibited"
In 1853, chemist Charles Frédéric Gerhardt treated sodium salicylate with acetyl chloride to produce acetylsalicylic acid for the first time; in the second half of the 19th century, other academic chemists established the compound's chemical structure and devised more efficient methods of synthesis. In 1897, scientists at the drug and dye firm Bayer began investigating acetylsalicylic acid as a less-irritating replacement for standard common salicylate medicines, and identified a new way to synthesize it. That year, Felix Hoffmann (or Arthur Eichengrün) of Bayer was the first to produce acetylsalicylic acid in a pure, stable form.
Salicylic acid had been extracted in 1838 from the herb meadowsweet, whose German name, Spirsäure, was the basis for naming the newly synthesized drug, which, by 1899, Bayer was selling globally. The word Aspirin was Bayer's brand name, rather than the generic name of the drug; however, Bayer's rights to the trademark were lost or sold in many countries. Aspirin's popularity grew over the first half of the 20th century, leading to fierce competition with the proliferation of aspirin brands and products.
Aspirin's popularity declined after the development of acetaminophen/paracetamol in 1956 and ibuprofen in 1962. In the 1960s and 1970s, John Vane and others discovered the basic mechanism of aspirin's effects, while clinical trials and other studies from the 1960s to the 1980s established aspirin's efficacy as an anti-clotting agent that reduces the risk of clotting diseases. The initial large studies on the use of low-dose aspirin to prevent heart attacks that were published in the 1970s and 1980s helped spur reform in clinical research ethics and guidelines for human subject research and US federal law, and are often cited as examples of clinical trials that included only men, but from which people drew general conclusions that did not hold true for women.
Aspirin sales revived considerably in the last decades of the 20th century, and remain strong in the 21st century with widespread use as a preventive treatment for heart attacks and strokes. |
Aspirin | Trademark | Trademark
Bayer lost its trademark for aspirin in the United States and some other countries in actions taken between 1918 and 1921 because it had failed to use the name for its own product correctly and had for years allowed the use of "Aspirin" by other manufacturers without defending the intellectual property rights. Aspirin is a generic trademark in many countries. Aspirin, with a capital "A", remains a registered trademark of Bayer in Germany, Canada, Mexico, and in over 80 other countries, for acetylsalicylic acid in all markets, but using different packaging and physical aspects for each. |
Aspirin | Compendial status | Compendial status
United States Pharmacopeia
British Pharmacopoeia |
Aspirin | Medical use | Medical use
Aspirin is used in the treatment of a number of conditions, including fever, pain, rheumatic fever, and inflammatory conditions, such as rheumatoid arthritis, pericarditis, and Kawasaki disease. Lower doses of aspirin have also been shown to reduce the risk of death from a heart attack, or the risk of stroke in people who are at high risk or who have cardiovascular disease, but not in elderly people who are otherwise healthy. There is evidence that aspirin is effective at preventing colorectal cancer, though the mechanisms of this effect are unclear. |
Aspirin | Pain | Pain
Aspirin is an effective analgesic for acute pain, although it is generally considered inferior to ibuprofen because aspirin is more likely to cause gastrointestinal bleeding. Aspirin is generally ineffective for those pains caused by muscle cramps, bloating, gastric distension, or acute skin irritation. As with other NSAIDs, combinations of aspirin and caffeine provide slightly greater pain relief than aspirin alone. Effervescent formulations of aspirin relieve pain faster than aspirin in tablets, which makes them useful for the treatment of migraines. Topical aspirin may be effective for treating some types of neuropathic pain.
Aspirin, either by itself or in a combined formulation, effectively treats certain types of a headache, but its efficacy may be questionable for others. Secondary headaches, meaning those caused by another disorder or trauma, should be promptly treated by a medical provider. Among primary headaches, the International Classification of Headache Disorders distinguishes between tension headache (the most common), migraine, and cluster headache. Aspirin or other over-the-counter analgesics are widely recognized as effective for the treatment of tension headaches. Aspirin, especially as a component of an aspirin/paracetamol/caffeine combination, is considered a first-line therapy in the treatment of migraine, and comparable to lower doses of sumatriptan. It is most effective at stopping migraines when they are first beginning. |
Aspirin | Fever | Fever
Like its ability to control pain, aspirin's ability to control fever is due to its action on the prostaglandin system through its irreversible inhibition of COX. Although aspirin's use as an antipyretic in adults is well established, many medical societies and regulatory agencies, including the American Academy of Family Physicians, the American Academy of Pediatrics, and the Food and Drug Administration, strongly advise against using aspirin for the treatment of fever in children because of the risk of Reye syndrome, a rare but often fatal illness associated with the use of aspirin or other salicylates in children during episodes of viral or bacterial infection. Because of the risk of Reye syndrome in children, in 1986, the US Food and Drug Administration (FDA) required labeling on all aspirin-containing medications advising against its use in children and teenagers. |
Aspirin | Inflammation | Inflammation
Aspirin is used as an anti-inflammatory agent for both acute and long-term inflammation, as well as for the treatment of inflammatory diseases, such as rheumatoid arthritis. |
Aspirin | Heart attacks and strokes | Heart attacks and strokes
Aspirin is an important part of the treatment of those who have had a heart attack. It is generally not recommended for routine use by people with no other health problems, including those over the age of 70.
The 2009 Antithrombotic Trialists' Collaboration published in Lancet evaluated the efficacy and safety of low dose aspirin in secondary prevention. In those with prior ischaemic stroke or acute myocardial infarction, daily low dose aspirin was associated with a 19% relative risk reduction of serious cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, or vascular death). This did come at the expense of a 0.19% absolute risk increase in gastrointestinal bleeding; however, the benefits outweigh the hazard risk in this case. Data from previous trials have suggested that weight-based dosing of aspirin has greater benefits in primary prevention of cardiovascular outcomes. However, more recent trials were not able to replicate similar outcomes using low dose aspirin in low body weight (<70 kg) in specific subset of population studied i.e. elderly and diabetic population, and more evidence is required to study the effect of high dose aspirin in high body weight (≥70 kg).
After percutaneous coronary interventions (PCIs), such as the placement of a coronary artery stent, a U.S. Agency for Healthcare Research and Quality guideline recommends that aspirin be taken indefinitely. Frequently, aspirin is combined with an ADP receptor inhibitor, such as clopidogrel, prasugrel, or ticagrelor to prevent blood clots. This is called dual antiplatelet therapy (DAPT). Duration of DAPT was advised in the United States and European Union guidelines after the CURE and PRODIGY studies. In 2020, the systematic review and network meta-analysis from Khan et al. showed promising benefits of short-term (< 6 months) DAPT followed by P2Y12 inhibitors in selected patients, as well as the benefits of extended-term (> 12 months) DAPT in high risk patients. In conclusion, the optimal duration of DAPT after PCIs should be personalized after outweighing each patient's risks of ischemic events and risks of bleeding events with consideration of multiple patient-related and procedure-related factors. Moreover, aspirin should be continued indefinitely after DAPT is complete.
The status of the use of aspirin for the primary prevention in cardiovascular disease is conflicting and inconsistent, with recent changes from previously recommending it widely decades ago, and that some referenced newer trials in clinical guidelines show less of benefit of adding aspirin alongside other anti-hypertensive and cholesterol lowering therapies. The ASCEND study demonstrated that in high-bleeding risk diabetics with no prior cardiovascular disease, there is no overall clinical benefit (12% decrease in risk of ischaemic events v/s 29% increase in GI bleeding) of low dose aspirin in preventing the serious vascular events over a period of 7.4 years. Similarly, the results of the ARRIVE study also showed no benefit of same dose of aspirin in reducing the time to first cardiovascular outcome in patients with moderate risk of cardiovascular disease over a period of five years. Aspirin has also been suggested as a component of a polypill for prevention of cardiovascular disease. Complicating the use of aspirin for prevention is the phenomenon of aspirin resistance. For people who are resistant, aspirin's efficacy is reduced. Some authors have suggested testing regimens to identify people who are resistant to aspirin.
As of , the United States Preventive Services Task Force (USPSTF) determined that there was a "small net benefit" for patients aged 40–59 with a 10% or greater 10-year cardiovascular disease (CVD) risk, and "no net benefit" for patients aged over 60. Determining the net benefit was based on balancing the risk reduction of taking aspirin for heart attacks and ischaemic strokes, with the increased risk of gastrointestinal bleeding, intracranial bleeding, and hemorrhagic strokes. Their recommendations state that age changes the risk of the medicine, with the magnitude of the benefit of aspirin coming from starting at a younger age, while the risk of bleeding, while small, increases with age, particular for adults over 60, and can be compounded by other risk factors such as diabetes and a history of gastrointestinal bleeding. As a result, the USPSTF suggests that "people ages 40 to 59 who are at higher risk for CVD should decide with their clinician whether to start taking aspirin; people 60 or older should not start taking aspirin to prevent a first heart attack or stroke." Primary prevention guidelines from made by the American College of Cardiology and the American Heart Association state they might consider aspirin for patients aged 40–69 with a higher risk of atherosclerotic CVD, without an increased bleeding risk, while stating they would not recommend aspirin for patients aged over 70 or adults of any age with an increased bleeding risk. They state a CVD risk estimation and a risk discussion should be done before starting on aspirin, while stating aspirin should be used "infrequently in the routine primary prevention of (atherosclerotic CVD) because of lack of net benefit". As of , the European Society of Cardiology made similar recommendations; considering aspirin specifically to patients aged less than 70 at high or very high CVD risk, without any clear contraindications, on a case-by-case basis considering both ischemic risk and bleeding risk. |
Aspirin | Cancer prevention | Cancer prevention
Aspirin may reduce the overall risk of both getting cancer and dying from cancer. There is substantial evidence for lowering the risk of colorectal cancer (CRC), but aspirin must be taken for at least 10–20 years to see this benefit. It may also slightly reduce the risk of endometrial cancer and prostate cancer.
Some conclude the benefits are greater than the risks due to bleeding in those at average risk. Others are unclear if the benefits are greater than the risk. Given this uncertainty, the 2007 United States Preventive Services Task Force (USPSTF) guidelines on this topic recommended against the use of aspirin for prevention of CRC in people with average risk. Nine years later however, the USPSTF issued a grade B recommendation for the use of low-dose aspirin (75 to 100mg/day) "for the primary prevention of CVD [cardiovascular disease] and CRC in adults 50 to 59 years of age who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years".
A meta-analysis through 2019 said that there was an association between taking aspirin and lower risk of cancer of the colorectum, esophagus, and stomach.
In 2021, the United States Preventive Services Task Force raised questions about the use of aspirin in cancer prevention. It notes the results of the 2018 ASPREE (Aspirin in Reducing Events in the Elderly) Trial, in which the risk of cancer-related death was higher in the aspirin-treated group than in the placebo group.
In 2025, a group of scientists at the University of Cambridge found that aspirin stimulates the immune system to reduce cancer metastasis. They found that a protein called ARHGEF1 suppresses T cells, that are required for attacking metastatic cancer cells. Aspirin appeared to counteract this suppression by targeting a clotting factor called thromboxane A2 (TXA2), which activates ARHGEF1, thus preventing it from suppressing the T cells. The researchers called the discovery a "Eureka moment". It was reported that the findings could lead to a more targeted use for aspirin in cancer research. It was also said that taking self-medicating with aspirin should not be done yet due to its potential side effects until clinical trials were held. |
Aspirin | Psychiatry | Psychiatry |
Aspirin | Bipolar disorder | Bipolar disorder
Aspirin, along with several other agents with anti-inflammatory properties, has been repurposed as an add-on treatment for depressive episodes in subjects with bipolar disorder in light of the possible role of inflammation in the pathogenesis of severe mental disorders. A 2022 systematic review concluded that aspirin exposure reduced the risk of depression in a pooled cohort of three studies (HR 0.624, 95% CI: 0.0503, 1.198, P=0.033). However, further high-quality, longer-duration, double-blind randomized controlled trials (RCTs) are needed to determine whether aspirin is an effective add-on treatment for bipolar depression. Thus, notwithstanding the biological rationale, the clinical perspectives of aspirin and anti-inflammatory agents in the treatment of bipolar depression remain uncertain. |
Aspirin | Dementia | Dementia
Although cohort and longitudinal studies have shown low-dose aspirin has a greater likelihood of reducing the incidence of dementia, numerous randomized controlled trials have not validated this. |
Aspirin | Schizophrenia | Schizophrenia
Some researchers have speculated the anti-inflammatory effects of aspirin may be beneficial for schizophrenia. Small trials have been conducted but evidence remains lacking. |
Aspirin | Other uses | Other uses
Aspirin is a first-line treatment for the fever and joint-pain symptoms of acute rheumatic fever. The therapy often lasts for one to two weeks, and is rarely indicated for longer periods. After fever and pain have subsided, the aspirin is no longer necessary, since it does not decrease the incidence of heart complications and residual rheumatic heart disease. Naproxen has been shown to be as effective as aspirin and less toxic, but due to the limited clinical experience, naproxen is recommended only as a second-line treatment.
Along with rheumatic fever, Kawasaki disease remains one of the few indications for aspirin use in children in spite of a lack of high quality evidence for its effectiveness.
Low-dose aspirin supplementation has moderate benefits when used for prevention of pre-eclampsia. This benefit is greater when started in early pregnancy.
Aspirin has also demonstrated anti-tumoral effects, via inhibition of the PTTG1 gene, which is often overexpressed in tumors. |
Aspirin | Resistance | Resistance
For some people, aspirin does not have as strong an effect on platelets as for others, an effect known as aspirin-resistance or insensitivity. One study has suggested women are more likely to be resistant than men, and a different, aggregate study of 2,930 people found 28% were resistant.
A study in 100 Italian people found, of the apparent 31% aspirin-resistant subjects, only 5% were truly resistant, and the others were noncompliant.
Another study of 400 healthy volunteers found no subjects who were truly resistant, but some had "pseudoresistance, reflecting delayed and reduced drug absorption".
Meta-analysis and systematic reviews have concluded that laboratory confirmed aspirin resistance confers increased rates of poorer outcomes in cardiovascular and neurovascular diseases. Although the majority of research conducted has surrounded cardiovascular and neurovascular, there is emerging research into the risk of aspirin resistance after orthopaedic surgery where aspirin is used for venous thromboembolism prophylaxis. Aspirin resistance in orthopaedic surgery, specifically after total hip and knee arthroplasties, is of interest as risk factors for aspirin resistance are also risk factors for venous thromboembolisms and osteoarthritis; the sequelae of requiring a total hip or knee arthroplasty. Some of these risk factors include obesity, advancing age, diabetes mellitus, dyslipidemia and inflammatory diseases. |
Aspirin | Dosages | Dosages
Adult aspirin tablets are produced in standardised sizes, which vary slightly from country to country, for example 300mg in Britain and 325mg in the United States. Smaller doses are based on these standards, e.g., 75mg and 81mg tablets. The 81 mg tablets are commonly called "baby aspirin" or "baby-strength", because they were originallybut no longerintended to be administered to infants and children. No medical significance occurs due to the slight difference in dosage between the 75mg and the 81mg tablets. The dose required for benefit appears to depend on a person's weight. For those weighing less than , low dose is effective for preventing cardiovascular disease; for patients above this weight, higher doses are required.
In general, for adults, doses are taken four times a day for fever or arthritis, with doses near the maximal daily dose used historically for the treatment of rheumatic fever. For the prevention of myocardial infarction (MI) in someone with documented or suspected coronary artery disease, much lower doses are taken once daily.
March 2009 recommendations from the USPSTF on the use of aspirin for the primary prevention of coronary heart disease encourage men aged 45–79 and women aged 55–79 to use aspirin when the potential benefit of a reduction in MI for men or stroke for women outweighs the potential harm of an increase in gastrointestinal hemorrhage. The WHI study of postmenopausal women found that aspirin resulted in a 25% lower risk of death from cardiovascular disease and a 14% lower risk of death from any cause, though there was no significant difference between 81mg and 325mg aspirin doses. The 2021 ADAPTABLE study also showed no significant difference in cardiovascular events or major bleeding between 81mg and 325mg doses of aspirin in patients (both men and women) with established cardiovascular disease.
Low-dose aspirin use was also associated with a trend toward lower risk of cardiovascular events, and lower aspirin doses (75 or 81mg/day) may optimize efficacy and safety for people requiring aspirin for long-term prevention.
In children with Kawasaki disease, aspirin is taken at dosages based on body weight, initially four times a day for up to two weeks and then at a lower dose once daily for a further six to eight weeks. |
Aspirin | Adverse effects | Adverse effects
thumb|Main side effects of aspirin
In October 2020, the US Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid. They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy. One exception to the recommendation is the use of low-dose 81mg aspirin at any point in pregnancy under the direction of a health care professional. |
Aspirin | Contraindications | Contraindications
Aspirin should not be taken by people who are allergic to ibuprofen or naproxen, or who have salicylate intolerance or a more generalized drug intolerance to NSAIDs, and caution should be exercised in those with asthma or NSAID-precipitated bronchospasm. Owing to its effect on the stomach lining, manufacturers recommend people with peptic ulcers, mild diabetes, or gastritis seek medical advice before using aspirin. Even if none of these conditions is present, the risk of stomach bleeding is still increased when aspirin is taken with alcohol or warfarin. People with hemophilia or other bleeding tendencies should not take aspirin or other salicylates. Aspirin is known to cause hemolytic anemia in people who have the genetic disease glucose-6-phosphate dehydrogenase deficiency, particularly in large doses and depending on the severity of the disease. Use of aspirin during dengue fever is not recommended owing to increased bleeding tendency. Aspirin taken at doses of ≤325 mg and ≤100 mg per day for ≥2 days can increase the odds of suffering a gout attack by 81% and 91% respectively. This effect may potentially be worsened by high purine diets, diuretics, and kidney disease, but is eliminated by the urate lowering drug allopurinol. Daily low dose aspirin does not appear to worsen kidney function. Aspirin may reduce cardiovascular risk in those without established cardiovascular disease in people with moderate CKD, without significantly increasing the risk of bleeding. Aspirin should not be given to children or adolescents under the age of 16 to control cold or influenza symptoms, as this has been linked with Reye syndrome. |
Aspirin | Gastrointestinal | Gastrointestinal
Aspirin increases the risk of upper gastrointestinal bleeding. Enteric coating on aspirin may be used in manufacturing to prevent release of aspirin into the stomach to reduce gastric harm, but enteric coating does not reduce gastrointestinal bleeding risk. Enteric-coated aspirin may not be as effective at reducing blood clot risk. Combining aspirin with other NSAIDs has been shown to further increase the risk of gastrointestinal bleeding. Using aspirin in combination with clopidogrel or warfarin also increases the risk of upper gastrointestinal bleeding.
The blockade of COX-1 by aspirin apparently results in the upregulation of COX-2 as part of a gastric defense. There is no clear evidence that simultaneous use of a COX-2 inhibitor with aspirin may increase the risk of gastrointestinal injury.
"Buffering" is an additional method used with the intent to mitigate gastrointestinal bleeding, such as by preventing aspirin from concentrating in the walls of the stomach, although the benefits of buffered aspirin are disputed. Almost any buffering agent used in antacids can be used; Bufferin, for example, uses magnesium oxide. Other preparations use calcium carbonate. Gas-forming agents in effervescent tablet and powder formulations can also double as a buffering agent, one example being sodium bicarbonate, used in Alka-Seltzer.
Taking vitamin C with aspirin has been investigated as a method of protecting the stomach lining. In trials, vitamin C-releasing aspirin (ASA-VitC) or a buffered aspirin formulation containing vitamin C was found to cause less stomach damage than aspirin alone. |
Aspirin | Retinal vein occlusion | Retinal vein occlusion
It is a widespread habit among eye specialists (ophthalmologists) to prescribe aspirin as an add-on medication for patients with retinal vein occlusion (RVO), such as central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). The reason of this widespread use is the evidence of its proven effectiveness in major systemic venous thrombotic disorders, and it has been assumed that may be similarly beneficial in various types of retinal vein occlusion.
However, a large-scale investigation based on data of nearly 700 patients showed "that aspirin or other antiplatelet aggregating agents or anticoagulants adversely influence the visual outcome in patients with CRVO and hemi-CRVO, without any evidence of protective or beneficial effect". Several expert groups, including the Royal College of Ophthalmologists, recommended against the use of antithrombotic drugs (incl. aspirin) for patients with RVO. |
Aspirin | Central effects | Central effects
Large doses of salicylate, a metabolite of aspirin, cause temporary tinnitus (ringing in the ears) based on experiments in rats, as the action on arachidonic acid and NMDA receptors cascade. |
Aspirin | Reye syndrome | Reye syndrome
Reye syndrome, a rare but severe illness characterized by acute encephalopathy and fatty liver, can occur when children or adolescents are given aspirin for a fever or other illness or infection. From 1981 to 1997, 1207 cases of Reye syndrome in people younger than 18 were reported to the US Centers for Disease Control and Prevention (CDC). Of these, 93% reported being ill in the three weeks preceding the onset of Reye syndrome, most commonly with a respiratory infection, chickenpox, or diarrhea. Salicylates were detectable in 81.9% of children for whom test results were reported. After the association between Reye syndrome and aspirin was reported, and safety measures to prevent it (including a Surgeon General's warning, and changes to the labeling of aspirin-containing drugs) were implemented, aspirin taken by children declined considerably in the United States, as did the number of reported cases of Reye syndrome; a similar decline was found in the United Kingdom after warnings against pediatric aspirin use were issued. The US Food and Drug Administration recommends aspirin (or aspirin-containing products) should not be given to anyone under the age of 12 who has a fever, and the UK National Health Service recommends children who are under 16 years of age should not take aspirin, unless it is on the advice of a doctor. |
Aspirin | Skin | Skin
For a small number of people, taking aspirin can result in symptoms including hives, swelling, and headache. Aspirin can exacerbate symptoms among those with chronic hives, or create acute symptoms of hives. These responses can be due to allergic reactions to aspirin, or more often due to its effect of inhibiting the COX-1 enzyme. Skin reactions may also tie to systemic contraindications, seen with NSAID-precipitated bronchospasm, or those with atopy.
Aspirin and other NSAIDs, such as ibuprofen, may delay the healing of skin wounds. Earlier findings from two small, low-quality trials suggested a benefit with aspirin (alongside compression therapy) on venous leg ulcer healing time and leg ulcer size, however, larger, more recent studies of higher quality have been unable to corroborate these outcomes. |
Aspirin | Other adverse effects | Other adverse effects
Aspirin can induce swelling of skin tissues in some people. In one study, angioedema appeared one to six hours after ingesting aspirin in some of the people. However, when the aspirin was taken alone, it did not cause angioedema in these people; the aspirin had been taken in combination with another NSAID-induced drug when angioedema appeared.
Aspirin causes an increased risk of cerebral microbleeds, having the appearance on MRI scans of 5 to 10mm or smaller, hypointense (dark holes) patches.
A study of a group with a mean dosage of aspirin of 270mg per day estimated an average absolute risk increase in intracerebral hemorrhage (ICH) of 12 events per 10,000 persons. In comparison, the estimated absolute risk reduction in myocardial infarction was 137 events per 10,000 persons, and a reduction of 39 events per 10,000 persons in ischemic stroke. In cases where ICH already has occurred, aspirin use results in higher mortality, with a dose of about 250mg per day resulting in a relative risk of death within three months after the ICH around 2.5 (95% confidence interval 1.3 to 4.6).
Aspirin and other NSAIDs can cause abnormally high blood levels of potassium by inducing a hyporeninemic hypoaldosteronism state via inhibition of prostaglandin synthesis; however, these agents do not typically cause hyperkalemia by themselves in the setting of normal renal function and euvolemic state.Medical knowledge self-assessment program for students 4, By American College of Physicians, Clerkship Directors in Internal Medicine, Nephrology 227, Item 29
Use of low-dose aspirin before a surgical procedure has been associated with an increased risk of bleeding events in some patients, however, ceasing aspirin prior to surgery has also been associated with an increase in major adverse cardiac events. An analysis of multiple studies found a three-fold increase in adverse events such as myocardial infarction in patients who ceased aspirin prior to surgery. The analysis found that the risk is dependent on the type of surgery being performed and the patient indication for aspirin use.
In July 2015, the US Food and Drug Administration (FDA) strengthened warnings of increased heart attack and stroke risk associated with nonsteroidal anti-inflammatory drugs (NSAID). Aspirin is an NSAID but is not affected by the revised warnings. |
Aspirin | Overdose | Overdose
thumb|Symptoms of aspirin overdose
Aspirin overdose can be acute or chronic. In acute poisoning, a single large dose is taken; in chronic poisoning, higher than normal doses are taken over a period of time. Acute overdose has a mortality rate of 2%. Chronic overdose is more commonly lethal, with a mortality rate of 25%; chronic overdose may be especially severe in children. (primary source) Toxicity is managed with a number of potential treatments, including activated charcoal, intravenous dextrose and normal saline, sodium bicarbonate, and dialysis. The diagnosis of poisoning usually involves measurement of plasma salicylate, the active metabolite of aspirin, by automated spectrophotometric methods. Plasma salicylate levels in general range from 30 to 100mg/L after usual therapeutic doses, 50–300mg/L in people taking high doses and 700–1400mg/L following acute overdose. Salicylate is also produced as a result of exposure to bismuth subsalicylate, methyl salicylate, and sodium salicylate. |
Aspirin | Interactions | Interactions
Aspirin is known to interact with other drugs. For example, acetazolamide and ammonium chloride are known to enhance the intoxicating effect of salicylates, and alcohol also increases the gastrointestinal bleeding associated with these types of drugs. Aspirin is known to displace a number of drugs from protein-binding sites in the blood, including the antidiabetic drugs tolbutamide and chlorpropamide, warfarin, methotrexate, phenytoin, probenecid, valproic acid (as well as interfering with beta oxidation, an important part of valproate metabolism), and other NSAIDs. Corticosteroids may also reduce the concentration of aspirin. Other NSAIDs, such as ibuprofen and naproxen, may reduce the antiplatelet effect of aspirin. Although limited evidence suggests this may not result in a reduced cardioprotective effect of aspirin. Analgesic doses of aspirin decrease sodium loss induced by spironolactone in the urine, however this does not reduce the antihypertensive effects of spironolactone. Furthermore, antiplatelet doses of aspirin are deemed too small to produce an interaction with spironolactone. Aspirin is known to compete with penicillin G for renal tubular secretion. Aspirin may also inhibit the absorption of vitamin C. |
Aspirin | Research | Research
The ISIS-2 trial demonstrated that aspirin at doses of 160mg daily for one month, decreased the mortality by 21% of participants with a suspected myocardial infarction in the first five weeks. A single daily dose of 324mg of aspirin for 12 weeks has a highly protective effect against acute myocardial infarction and death in men with unstable angina. |
Aspirin | Bipolar disorder | Bipolar disorder
Aspirin has been repurposed as an add-on treatment for depressive episodes in subjects with bipolar disorder. However, meta-analytic evidence is based on very few studies and does not suggest any efficacy of aspirin in the treatment of bipolar depression. Thus, notwithstanding the biological rationale, the clinical perspectives of aspirin and anti-inflammatory agents in the treatment of bipolar depression remain uncertain. |
Aspirin | Infectious diseases | Infectious diseases
Several studies investigated the anti-infective properties of aspirin for bacterial, viral and parasitic infections. Aspirin was demonstrated to limit platelet activation induced by Staphylococcus aureus and Enterococcus faecalis and to reduce streptococcal adhesion to heart valves. In patients with tuberculous meningitis, the addition of aspirin reduced the risk of new cerebral infarction [RR = 0.52 (0.29-0.92)]. A role of aspirin on bacterial and fungal biofilm is also being supported by growing evidence. |
Aspirin | Cancer prevention | Cancer prevention
Evidence from observational studies was conflicting on the effect of aspirin in breast cancer prevention; a randomized controlled trial showed that aspirin had no significant effect in reducing breast cancer, thus further studies are needed to clarify the effect of aspirin in cancer prevention. |
Aspirin | In gardening | In gardening
There are anecdotal reports that aspirin can improve the growth and resistance of plants, though most research has involved salicylic acid instead of aspirin. |
Aspirin | Veterinary medicine | Veterinary medicine
Aspirin is sometimes used in veterinary medicine as an anticoagulant or to relieve pain associated with musculoskeletal inflammation or osteoarthritis. Aspirin should be given to animals only under the direct supervision of a veterinarian, as adverse effects—including gastrointestinal issues—are common. An aspirin overdose in any species may result in salicylate poisoning, characterized by hemorrhaging, seizures, coma, and even death.
Dogs are better able to tolerate aspirin than cats are. Cats metabolize aspirin slowly because they lack the glucuronide conjugates that aid in the excretion of aspirin, making it potentially toxic if dosing is not spaced out properly. No clinical signs of toxicosis occurred when cats were given 25mg/kg of aspirin every 48 hours for 4 weeks, but the recommended dose for relief of pain and fever and for treating blood clotting diseases in cats is 10mg/kg every 48 hours to allow for metabolization. |
Aspirin | References | References |
Aspirin | Further reading | Further reading
|
Aspirin | External links | External links
Category:1897 in Germany
Category:1897 in science
Category:Acetate esters
Category:Acetylsalicylic acids
Category:Antiplatelet drugs
Category:Drugs developed by Bayer
Category:Brands that became generic
Category:Chemical substances for emergency medicine
Category:Commercialization of traditional medicines
Category:Covalent inhibitors
Category:Equine medications
Category:German inventions
Category:Hepatotoxins
Category:Nonsteroidal anti-inflammatory drugs
Category:Salicylic acids
Category:Salicylyl esters
Category:World Health Organization essential medicines
Category:Wikipedia medicine articles ready to translate |
Aspirin | Table of Content | Short description, Brand vs. generic name, Chemical properties, Synthesis, Physical properties, Polymorphism, Mechanism of action, Discovery of the mechanism, Prostaglandins and thromboxanes, COX-1 and COX-2 inhibition, Additional mechanisms, Formulations, Pharmacokinetics, History, Trademark, Compendial status, Medical use, Pain, Fever, Inflammation, Heart attacks and strokes, Cancer prevention, Psychiatry, Bipolar disorder, Dementia, Schizophrenia, Other uses, Resistance, Dosages, Adverse effects, Contraindications, Gastrointestinal, Retinal vein occlusion, Central effects, Reye syndrome, Skin, Other adverse effects, Overdose, Interactions, Research, Bipolar disorder, Infectious diseases, Cancer prevention, In gardening, Veterinary medicine, References, Further reading, External links |
Abner | Short description | thumb|Abner (in green) taking Michal away from Paltiel (Morgan Bible, 1240s).
In the Hebrew Bible, Abner ( ) was the cousin of King Saul and the commander-in-chief of his army., His name also appears as "Abiner son of Ner", where the longer form Abiner means "my father is Ner". |
Abner | Biblical narrative | Biblical narrative
Abner is initially mentioned incidentally in Saul's history,, , ) first appearing as the son of Ner, Saul's uncle, and the commander of Saul's army. He then comes to the story again as the commander who introduced David to Saul following David's killing of Goliath. He is not mentioned in the account of the disastrous battle of Gilboa when Saul's power was crushed. Seizing the youngest but only surviving of Saul's sons, Ish-bosheth, also called Eshbaal, Abner set him up as king over Israel at Mahanaim, east of the Jordan. David, who was accepted as king by Judah alone, was meanwhile reigning at Hebron, and for some time war was carried on between the two parties.
The only engagement between the rival factions told at length was preceded by an encounter at Gibeon between 12 chosen men from each side, in which all 24 seem to have perished. In the general engagement which followed, Abner was defeated and put to flight. He was closely pursued by Asahel, brother of Joab, who is said to have been "light of foot as a wild roe". As Asahel would not desist from the pursuit, though warned, Abner was compelled to slay him in self-defense, planting his spear in the ground and allowing Asahel to impale himself. This originated a deadly feud between the leaders of the opposite parties, for Joab, as next of kin to Asahel, was by the law and custom of the country the avenger of his blood. However, according to Josephus, in Antiquities, book 7, chapter 1, Joab had forgiven Abner for the death of his brother, Asahel, the reason being that Abner had slain Asahel honorably in combat after he had first warned Asahel and tried to knock the wind out of him with the butt of his spear.
thumb|250px|Abner with Rizpah
For some time afterward, the war was carried on, the advantage being invariably on the side of David. At length, Ish-bosheth lost the main prop of his tottering cause by accusing Abner of sleeping with Rizpah,cf. one of Saul's concubines, an alliance which, according to contemporary notions, would imply pretensions to the throne.cf. ff.
Abner was indignant at the rebuke, and immediately opened negotiations with David, who welcomed him on the condition that his wife Michal should be restored to him. This was done, and the proceedings were ratified by a feast. Almost immediately after, however, Joab, who had been sent away, perhaps intentionally, returned and slew Abner at the gate of Hebron. The ostensible motive for the assassination was a desire to avenge Asahel, and this would be a sufficient justification for the deed according to the moral standard of the time (although Abner should have been safe from such a revenge killing in Hebron, which was a City of Refuge). The conduct of David after the event was such as to show that he had no complicity in the act, though he could not venture to punish its perpetrators.; cf. ff.
David had Abner buried in Hebron, as stated in 2 Samuel 3:31–32, "And David said to all the people who were with him, 'Rend your clothes and gird yourselves with sackcloth, and wail before Abner.' And King David went after the bier. And they buried Abner in Hebron, and the king raised his voice and wept on Abner's grave, and all the people wept."
Shortly after Abner's death, Ish-bosheth was assassinated as he slept, and David became king of the reunited kingdoms. |
Abner | Rabbinical literature | Rabbinical literature
Midrashic writings establish Abner as the son of the Witch of En-dor (Pirḳe R. El. xxxiii.), and the hero par excellence in the Haggadah (Yalḳ., Jer. 285; Eccl. R. on ix. 11; Ḳid. 49b). Conscious of his extraordinary strength, he exclaimed: "If I could only catch hold of the earth, I could shake it" (Yalḳ. l.c.)—a saying which parallels the famous utterance of Archimedes, "Had I a fulcrum, I could move the world." According to the Midrash (Eccl. R. l.c.) it would have been easier to move a wall six yards thick than one of the feet of Abner, who could hold the Israelitish army between his knees. Yet when his time came, Joab smote him. But even in his dying hour, Abner seized his foe like a ball of thread, threatening to crush him. Then the Israelites came and pleaded for Joab's life, saying: "If thou killest him we shall be orphaned, and our women and all our belongings will become a prey to the Philistines." Abner answered: "What can I do? He has extinguished my light" (has wounded me fatally). The Israelites replied: "Entrust thy cause to the true judge [God]." Then Abner released his hold upon Joab and fell dead to the ground (Yalḳ. l.c.).
The rabbis agree that Abner deserved this violent death, though opinions differ concerning the exact nature of the sin that entailed so dire a punishment on one who was, on the whole, considered a "righteous man" (Gen. R. lxxxii. 4). Some reproach him that he did not use his influence with Saul to prevent him from murdering the priests of Nob (Yer. Peah, i. 16a; Lev. R. xxvi. 2; Sanh. 20a)—convinced as he was of the innocence of the priests and of the propriety of their conduct toward David, Abner holding that as leader of the army David was privileged to avail himself of the Urim and Thummim (I Sam. xxii. 9–19). Instead of contenting himself with passive resistance to Saul's command to murder the priests (Yalḳ., Sam. 131), Abner ought to have tried to restrain the king. Others maintain that Abner did make such an attempt, but in vain, and that his one sin consisted in that he delayed the beginning of David's reign over Israel by fighting him after Saul's death for two years and a half (Sanh. l.c.). Others, again, while excusing him for this—in view of a tradition founded on Gen. xlix. 27, according to which there were to be two kings of the house of Benjamin—blame Abner for having prevented a reconciliation between Saul and David on the occasion when the latter, in holding up the skirt of Saul's robe (I Sam. xxiv. 11), showed how unfounded was the king's mistrust of him. Saul was inclined to be pacified; but Abner, representing to him that David might have found the piece of the garment anywhere—possibly caught on a thorn—prevented the reconciliation (Yer. Peah, l.c., Lev. R. l.c., and elsewhere). Moreover, it was wrong in Abner to permit Israelitish youths to kill one another for sport (II Sam. ii. 14–16). No reproach, however, attaches to him for the death of Asahel, since Abner killed him in self-defense (Sanh. 49a).
It is characteristic of the rabbinical view of the Bible narratives that Abner, the warrior pure and simple, is styled "Lion of the Law" (Yer. Peah, l.c.), and that even a specimen is given of a halakic discussion between him and Doeg as to whether the law in Deut. xxiii. 3 excluded Ammonite and Moabite women from the Jewish community as well as men. Doeg was of the opinion that David, being descended from the Moabitess Ruth, was not fit to wear the crown, nor even to be considered a true Israelite; while Abner maintained that the law affected only the male line of descent. When Doeg's dialectics proved more than a match for those of Abner, the latter went to the prophet Samuel, who not only supported Abner in his view, but utterly refuted Doeg's assertions (Midr. Sam. xxii.; Yeb. 76b et seq.).
One of the most prominent families (Ẓiẓit ha-Kesat) in Jerusalem in the middle of the first century of the common era claimed descent from Abner (Gen. R. xcviii.). |
Abner | Tomb of Abner | Tomb of Abner
The site known as the Tomb of Abner is located not far from the Cave of the Patriarchs in Hebron and receives visitors throughout the year. Many travelers have recorded visiting the tomb over the centuries.
thumb|David and the tomb of Abner. Artist unknown. 19th century. Benjamin of Tudela, who began his journeys in 1165, wrote in the journal, "The valley of Eshkhol is north of the mountain upon which Hebron stood, and the cave of Makhpela is east thereof. A bow-shot west of the cave is the sepulchre of Abner the son of Ner."
A rabbi in the 12th century records visiting the tomb as reprinted in Elkan Nathan Adler's book Jewish Travellers in the Middle Ages: 19 Firsthand Accounts. The account states, "I, Jacob, the son of R. Nathaniel ha Cohen, journeyed with much difficulty, but God helped me to enter the Holy Land, and I saw the graves of our righteous Patriarchs in Hebron and the grave of Abner the son of Ner." Adler postulates that the visit must have occurred prior to Saladin's capture of Jerusalem in 1187.
Rabbi Moses Basola records visiting the tomb in 1522. He states, "Abner's grave is in the middle of Hebron; the Muslims built a mosque over it." Another visitor in the 1500s states that "at the entrance to the market in Hebron, at the top of the hill against the wall, Abner ben Ner is buried, in a church, in a cave." This visit was recorded in Sefer Yihus ha-Tzaddiqim (Book of Genealogy of the Righteous), a collection of travelogues from 1561. Abraham Moshe Lunz reprinted the book in 1896.
Menahem Mendel of Kamenitz, considered the first hotelier in the Land of Israel, wrote about the Tomb of Abner is his 1839 book Korot Ha-Itim, which was translated into English as The Book of the Occurrences of the Times to Jeshurun in the Land of Israel. He states, "Here I write of the graves of the righteous to which I paid my respects. Hebron – Described above is the character and order of behavior of those coming to pray at the Cave of ha-Machpelah. I went there, between the stores, over the grave of Avner ben Ner and was required to pay a Yishmaeli – the grave was in his courtyard – to allow me to enter."
The author and traveler J. J. Benjamin mentioned visiting the tomb in his book Eight Years in Asia and Africa (1859, Hanover). He states, "On leaving the Sepulchre of the Patriarchs, and proceeding on the road leading to the Jewish quarter, to the left of the courtyard, is seen a Turkish dwelling house, by the side of which is a small grotto, to which there is a descent of several steps. This is the tomb of Abner, captain of King Saul. It is held in much esteem by the Arabs, and the proprietor of it takes care that it is always kept in the best order. He requires from those who visit it a small gratuity."
The British scholar Israel Abrahams wrote in his 1912 book The Book of Delight and Other Papers, "Hebron was the seat of David's rule over Judea. Abner was slain here by Joab, and was buried here – they still show Abner's tomb in the garden of a large house within the city. By the pool at Hebron were slain the murderers of Ishbosheth..."
thumb|Tomb of Abner
Over the years the tomb fell into disrepair and neglect. It was closed to the public in 1994. In 1996, a group of 12 Israeli women filed a petition with the Supreme Court requesting the government to reopen the Tomb of Abner. More requests were made over the years and eventually arrangements were made to have the site open to the general public on ten days throughout the year corresponding to the ten days that the Isaac Hall of the Cave of the Patriarchs is open. In early 2007 new mezuzot were affixed to the entrance of the site. |
Abner | In popular culture | In popular culture
1960, David and Goliath (film) – Abner is portrayed by Massimo Serato. In this version, Abner tries to murder David (Ivica Pajer) when he returns in triumph after killing Goliath. However, here Abner is slain by King Saul (Orson Welles).
1961, A Story of David (film) – Abner is portrayed by Welsh actor David Davies.
1976, The Story of David (television series) – Younger version of Abner is portrayed by Israeli actor Yehuda Efroni. Older version of Abner is portrayed by British actor Brian Blessed.
1985, King David (film) – Abner is portrayed by English actor John Castle. King David portrayed by Richard Gere.
1997, King David (musical) – written by Tim Rice and Alan Menken. Abner is portrayed by American actor Timothy Shew.
1997, David (television drama) – Abner is portrayed by Richard Ashcroft.
2009, Kings (television series) – Abner portrayed by Wes Studi as General Linus Abner. The series is set in a multi-ethnic Western culture similar to that in the present-day United States, but with characters drawn from the Bible.
2012, Rei Davi (Brazilian television series) – Abner is portrayed by Iran Malfitano.
2025, House of David – Abner is portrayed by Oded Fehr |
Abner | Notes | Notes |
Abner | References | References |
Abner | Citations | Citations |
Abner | Cited sources | Cited sources
|
Abner | External links | External links
Pictures of Avner ben Ner's Tomb in Hebron
Tomb of Abner page on Hebron.com website.
David, Abraham (ed.) (1999). In Zion and Jerusalem: The Itinerary of Rabbi Moses Basola (1521–1523) C. G. Foundation Jerusalem Project Publications of the Martin (Szusz) Department of Land of Israel Studies of Bar-Ilan University . Reference is made to visiting the tomb of Abner. (p. 77).
Photo of prayer at the Tomb of Abner from Imagekind.
Photo of prayer at the Tomb of Abner from PicJew.
Photos of Tomb of Abner Ben Ner from the book Sites in Hebron by David Wilder. ASIN: B00ALHB89Y.
Category:Biblical murder victims
Category:Warriors of Asia
Category:House of Saul
ca:Llista de personatges bíblics#Abner |
Abner | Table of Content | Short description, Biblical narrative, Rabbinical literature, Tomb of Abner, In popular culture, Notes, References, Citations, Cited sources, External links |
Ahmed I | Short description | alt=Sultan|thumb|Sultan Ahmed I
Ahmed I ( ; ; 18 April 1590 – 22 November 1617) was the sultan of the Ottoman Empire from 1603 to 1617. Ahmed's reign is noteworthy for marking the first breach in the Ottoman tradition of royal fratricide; henceforth, Ottoman rulers would no longer systematically execute their brothers upon accession to the throne. He is also well known for his construction of the Blue Mosque, one of the most famous mosques in Turkey. |
Ahmed I | Early life | Early life
Ahmed was born at the Manisa Palace, Manisa, probably on 18 April 1590, when his father Mehmed was still a prince and the governor of the Sanjak of Manisa. His mother was Handan Sultan. After his grandfather Murad III's death in 1595, his father came to Constantinople and ascended the throne as Sultan Mehmed III. Mehmed ordered the execution of his nineteen half brothers. Ahmed's elder brother Şehzade Mahmud was also executed by his father Mehmed on 7 June 1603, just before Mehmed's own death on 22 December 1603. Mahmud was buried along with his mother (Halime Sultan, dead after 1623) in a separate mausoleum built by Ahmed in Şehzade Mosque, Constantinople. |
Ahmed I | Reign | Reign
Ahmed ascended the throne after his father's death in 1603, at the age of thirteen, when his powerful grandmother Safiye Sultan was still alive. With his accession to the throne, the power struggle in the harem flared up; between his mother Handan Sultan and his grandmother Safiye Sultan, who in the previous reign had absolute power within the walls (behind the throne), in the end, with the support of Ahmed, the fight ended in favor of his mother. Ahmed broke with the traditional fratricide following previous enthronements and did not order the execution of his three years old half-brother Mustafa, the second son of Halime Sultan. Instead, Mustafa was sent to live at the old palace at Bayezit along with his mother and their grandmother, Safiye Sultan. This was most likely due to Ahmed's young age - he had not yet demonstrated his ability to sire children, and Mustafa was then the only other candidate for the Ottoman throne. His brother's execution would have endangered the dynasty, and thus he was spared.
His mother tried to interfere in his affairs and influence his decision, especially she wanted to control his communication and movements. In the earlier part of his reign, Ahmed I showed decision and vigor, which were belied by his subsequent conduct. The wars in Hungary and Persia, which attended his accession, terminated unfavourably for the empire. Its prestige was further tarnished in the Treaty of Zsitvatorok, signed in 1606, whereby the annual tribute paid by Austria was abolished. Following the crushing defeat in the Ottoman–Safavid War (1603–1612) against the neighbouring rivals Safavid Empire, led by Shah Abbas the Great, Georgia, Azerbaijan and other vast territories in the Caucasus were ceded back to Persia per the Treaty of Nasuh Pasha in 1612, territories that had been temporarily conquered in the Ottoman–Safavid War (1578–90). The new borders were drawn per the same line as confirmed in the Peace of Amasya of 1555.Ga ́bor A ́goston,Bruce Alan Masters Encyclopedia of the Ottoman Empire pp 23 Infobase Publishing, 1 jan. 2009 |
Ahmed I | Relations with Morocco | Relations with Morocco
During his reign the ruler of Morocco was Mulay Zidan whose father and predecessor Ahmad al-Mansur had paid a tribute of vassalage as a vassal of the Ottomans until his death.Revue française d'histoire d'outre-mer, Volume 17.Histoire du Maroc. Coissac de Chavrebière. Payot. The Saadi civil wars had interrupted this tribute of vassalage, but Mulay Zidan proposed to submit to it in order to protect himself from Algiers, and so he resumed paying the tribute to the Ottomans.Les Sources inédites de l'histoire du Maroc de 1530 à 1845. E. Leroux. |
Ahmed I | Ottoman-Safavid War: 1604–06 | Ottoman-Safavid War: 1604–06
The Ottoman–Safavid War had begun shortly before the death of Ahmed's father Mehmed III. Upon ascending the throne, Ahmed I appointed Cigalazade Yusuf Sinan Pasha as the commander of the eastern army. The army marched from Constantinople on 15 June 1604, which was too late, and by the time it had arrived on the eastern front on 8 November 1604, the Safavid army had captured Yerevan and entered the Kars Eyalet, and could only be stopped in Akhaltsikhe. Despite the conditions being favourable, Sinan Pasha decided to stay for the winter in Van, but then marched to Erzurum to stop an incoming Safavid attack. This caused unrest within the army and the year was practically wasted for the Ottomans.
In 1605, Sinan Pasha marched to take Tabriz, but the army was undermined by Köse Sefer Pasha, the Beylerbey of Erzurum, marching independently from Sinan Pasha and consequently being taken prisoner by the Safavids. The Ottoman army was routed at Urmia and had to flee firstly to Van and then to Diyarbekir. Here, Sinan Pasha sparked a rebellion by executing the Beylerbey of Aleppo, Canbulatoğlu Hüseyin Pasha, who had come to provide help, upon the pretext that he had arrived too late. He soon died himself and the Safavid army was able to capture Ganja, Shirvan and Shamakhi in Azerbaijan. |
Ahmed I | War with the Habsburgs: 1604–06 | War with the Habsburgs: 1604–06
The Long Turkish War between the Ottomans and the Habsburg monarchy had been going on for over a decade by the time Ahmed ascended the throne. Grand Vizier Malkoç Ali Pasha marched to the western front from Constantinople on 3 June 1604 and arrived in Belgrade, but died there, so Sokolluzade Lala Mehmed Pasha was appointed as the Grand Vizier and the commander of the western army. Under Mehmed Pasha, the western army recaptured Pest and Vác, but failed to capture Esztergom as the siege was lifted due to unfavourable weather and the objections of the soldiers. Meanwhile, the Prince of Transylvania, Stephen Bocskay, who struggled for the region's independence and had formerly supported the Habsburgs, sent a messenger to the Porte asking for help. Upon the promise of help, his forces also joined the Ottoman forces in Belgrade. With this help, the Ottoman army besieged Esztergom and captured it on 4 November 1605. Bocskai, with Ottoman help, captured Nové Zámky (Uyvar) and forces under Tiryaki Hasan Pasha took Veszprém and Palota. Sarhoş İbrahim Pasha, the Beylerbey of Nagykanizsa (Kanije), attacked the Austrian region of Istria.
thumb|Ottoman miniature of Ahmed I. |310x310px
However, with Jelali revolts in Anatolia more dangerous than ever and a defeat in the eastern front, Mehmed Pasha was called to Constantinople. Mehmed Pasha suddenly died there, whilst preparing to leave for the east. Kuyucu Murad Pasha then negotiated the Peace of Zsitvatorok, which abolished the tribute of 30,000 ducats paid by Austria and addressed the Habsburg emperor as the equal of the Ottoman sultan. The Jelali revolts were a strong factor in the Ottomans' acceptance of the terms. This signaled the end of Ottoman growth in Europe. |
Ahmed I | Jelali revolts | Jelali revolts
Resentment over the war with the Habsburgs and heavy taxation, along with the weakness of the Ottoman military response, combined to make the reign of Ahmed I the zenith of the Jelali revolts. Tavil Ahmed launched a revolt soon after the coronation of Ahmed I and defeated Nasuh Pasha and the Beylerbey of Anatolia, Kecdehan Ali Pasha. In 1605, Tavil Ahmed was offered the position of the Beylerbey of Shahrizor to stop his rebellion, but soon afterwards he went on to capture Harput. His son, Mehmed, obtained the governorship of Baghdad with a fake firman and defeated the forces of Nasuh Pasha sent to defeat him.
Meanwhile, Canbulatoğlu Ali Pasha united his forces with the Druze Sheikh Ma'noğlu Fahreddin to defeat the Amir of Tripoli Seyfoğlu Yusuf. He went on to take control of the Adana area, forming an army and issuing coins. His forces routed the army of the newly appointed Beylerbey of Aleppo, Hüseyin Pasha. Grand Vizier Boşnak Dervish Mehmed Pasha was executed for the weakness he showed against the Jelalis. He was replaced by Kuyucu Murad Pasha, who marched to Syria with his forces to defeat the 30,000-strong rebel army with great difficulty, albeit with a decisive result, on 24 October 1607. Meanwhile, he pretended to forgive the rebels in Anatolia and appointed the rebel Kalenderoğlu, who was active in Manisa and Bursa, as the sanjakbey of Ankara. Baghdad was recaptured in 1607 as well. Canbulatoğlu Ali Pasha fled to Constantinople and asked for forgiveness from Ahmed I, who appointed him to Timișoara and later Belgrade, but then executed him due to his misrule there. Meanwhile, Kalenderoğlu was not allowed in the city by the people of Ankara and rebelled again, only to be crushed by Murad Pasha's forces. Kalenderoğlu ended up fleeing to Persia. Murad Pasha then suppressed some smaller revolts in Central Anatolia and suppressed other Jelali chiefs by inviting them to join the army.
Due to the widespread violence of the Jelali revolts, a great number of people had fled their villages and a lot of villages were destroyed. Some military chiefs had claimed these abandoned villages as their property. This deprived the Porte of tax income and on 30 September 1609, Ahmed I issued a letter guaranteeing the rights of the villagers. He then worked on the resettlement of abandoned villages. |
Ahmed I | Ottoman-Safavid War: Peace and continuation | Ottoman-Safavid War: Peace and continuation
thumb|200px|Bilingual Franco-Turkish translation of the 1604 Franco-Ottoman Capitulations between Ahmed I and Henry IV of France, published by François Savary de Brèves in 1615
The new Grand Vizier, Nasuh Pasha, did not want to fight with the Safavids. The Safavid Shah also sent a letter saying that he was willing to sign a peace treaty, with which he would have to send 200 loads of silk every year to Constantinople. On 20 November 1612, the Treaty of Nasuh Pasha was signed, which ceded all the lands the Ottoman Empire had gained in the war of 1578–90 back to Persia and reinstated the 1555 boundaries.
However, the peace ended in 1615 when the Shah did not send the 200 loads of silk. On 22 May 1615, Grand Vizier Öküz Mehmed Pasha was assigned to organize an attack on Persia. Mehmed Pasha delayed the attack till the next year, until when the Safavids made their preparations and attacked Ganja. In April 1616, Mehmed Pasha left Aleppo with a large army and marched to Yerevan, where he failed to take the city and withdrew to Erzurum. He was removed from his post and replaced by Damat Halil Pasha. Halil Pasha went for the winter to Diyarbekir, while the Khan of Crimea, Canibek Giray, attacked the areas of Ganja, Nakhichevan and Julfa. |
Ahmed I | Capitulations and trade treaties | Capitulations and trade treaties
Ahmed I renewed trade treaties with England, France and Venice. In July 1612, the first ever trade treaty with the Dutch Republic was signed. He expanded the capitulations given to France, specifying that merchants from Spain, Ragusa, Genoa, Ancona and Florence could trade under the French flag. |
Ahmed I | Architect and service to Islam | Architect and service to Islam
thumb|Ahmed I plate at Masjid al-Nabawi marking Bab al-Tawba|267x267px
Sultan Ahmed constructed the Sultan Ahmed Mosque, the magnum opus of the Ottoman architecture, across from the Hagia Sophia. The sultan attended the breaking of the ground with a golden pickaxe to begin the construction of the mosque complex. An incident nearly broke out after the sultan discovered that the Blue Mosque contained the same number of minarets as the grand mosque of Mecca. Ahmed became furious at this fault and became remorseful until the Shaykh-ul-Islam recommended that he should erect another minaret at the grand mosque of Mecca and the matter was solved.
thumb|200x200px|The Sultan Ahmed Mosque|left
Ahmed became delightedly involved in the eleventh comprehensive renovations of the Kaaba, which had just been damaged by flooding. He sent craftsmen from Constantinople, and the golden rain gutter that kept rain from collecting on the roof of the Ka’ba was successfully renewed. It was again during the era of Sultan Ahmed that an iron web was placed inside the Zamzam Well in Mecca. The placement of this web about three feet below the water level was a response to lunatics who jumped into the well, imagining a promise of a heroic death.
In Medina, the city of the Islamic prophet Muhammad, a new pulpit made of white marble and shipped from Istanbul arrived in the mosque of Muhammad and substituted the old, worn-out pulpit. It is also known that Sultan Ahmed erected two more mosques in Uskudar on the Asian side of Istanbul; however, neither of them has survived.
The sultan had a crest carved with the footprint of Muhammad that he would wear on Fridays and festive days and illustrated one of the most significant examples of affection to Muhammad in Ottoman history. Engraved inside the crest was a poem he composed: |
Ahmed I | Character | Character
Sultan Ahmed was known for his skills in fencing, poetry, horseback riding, and fluency in several languages.
Ahmed was a poet who wrote a number of political and lyrical works under the name Bahti. Ahmed patronized scholars, calligraphers, and pious men. Hence, he commissioned a book entitled The Quintessence of Histories to be worked upon by calligraphers. He also attempted to enforce conformance to Islamic laws and traditions, restoring the old regulations that prohibited alcohol, and he attempted to enforce attendance at Friday prayers and paying alms to the poor in the proper way. |
Ahmed I | Death | Death
thumb|220x220px|Ahmed I's türbe
Ahmed I died of typhus and gastric bleeding on 22 November 1617 at the Topkapı Palace, Istanbul. He was buried in Ahmed I Mausoleum, Sultan Ahmed Mosque. He was succeeded by his younger half-brother Mustafa as Sultan Mustafa I. Later three of Ahmed's sons ascended to the throne: Osman II (r. 1618–22), Murad IV (r. 1623–40) and Ibrahim (r. 1640–48). |
Ahmed I | Family | Family |
Ahmed I | Consorts | Consorts
Ahmed had two known consorts, besides many unknown concubinesVenetian ambassador, Simone Contarini (May 1612): “Ha il re due figliuoli, l’uno di sette, l’altro di sei. […] Tre figliuole femmine si trova avere anco Sua Maestà alla quale nascon pure de’ figliuoli assai spesso, e per l’abbondanza delle donne, e per la gioventù, e prosperità che tiene.”, mothers of the other Şehzades and Sultanas.
The known consorts are:
Hatice Mahfiruz Hatun ( - ?) first consort and mother to his firstborn son Osman II and most possibly other children including three other sons according to various historians including Öztuna.
Kösem Sultan ( - 2 September 1651). She was his favourite consort, Haseki Sultan, and the mother of many of his children, among them the future Murad IV and Ibrahim I. |
Ahmed I | Sons | Sons
Ahmed I had at least thirteen sons:
Osman II (3 November 1604, Constantinople, Topkapı Palace – murdered by janissaries, 20 May 1622, Constantinople, Topkapı Palace, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque) - with Mahfiruz Hatun. 16th Sultan of the Ottoman Empire;
Şehzade Mehmed (11 March 1605, Constantinople, Topkapı Palace – executed by orders of Osman II, 12 January 1621, Istanbul, Topkapı Palace, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque) - with Kösem Sultan ;
Şehzade Orhan (1609, Constantinople – 1612, Constantinople, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque.Yılmaz Öztuna - Sultan Genç Osman ve Sultan IV. Murad
Şehzade Cihangir (1609, Constantinople – 1609, Constantinople, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque).
Şehzâde Fülane (1610/1611, Constantinople -1612, Constantinople) : He died a year after his birth according to the 1612 report of Venetian Bailo Contarini.Tezcan, Baki: The Debut of Kösem Sultan's Career; pp 348; "...before the birth of Murad, that besides the two princes alive, Ahmed had two other sons; one of them died soon after his birth [Selim], and the other a year after his birth; see Nicolo BAROZZI and Guglielmo BERCHET, eds., Le relazioni degli stati
europei lette al senato dagli ambasciatori veneziani nel secolo decimosettimo: Turchia, 2 vols., Venice, 1871-72, vol. 1, p. 125-254, at p. 133 [reprinted in Luigi FIRPO, ed., Relazioni di ambasciatori veneti al senato, tratte dalle migliori edizioni disponibili e ordinate cronologicamente, vol. 13: Constantinopoli (1590-1793), Torino, Bottega d’Erasmo, 1984, p. 473-602, at p. 481].
Şehzade Selim (27 June 1611, Constantinople – 27 July 1611, Constantinople, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque).
Murad IV (27 July 1612, Constantinople – 8 February 1640, Constantinople, Topkapı Palace, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque) - with Kösem Sultan. 17th Sultan of the Ottoman Empire;
Şehzade Bayezid (December 1612, Constantinople – murdered by Murad IV, 27 July 1635, Constantinople, Topkapı Palace, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque)-With Mahfiruz Hatun;
Şehzade Hüseyin (November 1613,Tezcan, Baki: The Debut of Kösem Sultan's Career; pp 354; fn 40: SAFI, Zübdetü’t-Tevârîh, op. cit., vol. 2, p. 300 Constantinople – 1617, Constantinople, Topkapı Palace, buried in Mehmed III Mausoleum, Hagia Sophia Mosque) with Mahfiruz Hatun;
Şehzade Hasan (1614/15,Tezcan, Baki: The Debut of Kösem Sultan's Career; pp 354 Constantinople – 1615, Constantinople, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque)
Şehzade Süleyman (1615/16,Tezcan , Baki: The Debut of Kösem Sultan's Career pp 354; HASANBEYZADE, Hasan Bey-zâde Târîhi, op. cit., vol. 3, p. 899; KARAÇELEBIZADE, Ravzatü’l-ebrâr, op. cit., p. 534 Constantinople – executed by orders Murad IV, 27 July 1635, Constantinople, Topkapı Palace, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque) - with Mahfiruz Hatun. Some historians have confused Süleyman with Selim (who had died in 1611 barely a few weeks after his birth according to the Venetian bailo, Contarini's report of 1612) and also with Hüseiyn, but this is a false claim as only Murad, Bayezid, Süleyman, Kasim and Ibrahim were alive during 1622 according to Harem registers and those that were executed by Murad IV were his half-brothers Bayezid and Süleyman on July 27, 1635 and then (most probably Murad's full-brother) Şehzâde Kasim on 17 February 1638.Tezcan , Baki: The Debut of Kösem Sultan's Career pp 355Gülru Neci̇poğlu, Julia Bailey (2008). Frontiers of Islamic Art and Architecture: Essays in Celebration of Oleg Grabar's Eightieth Birthday ; the Aga Khan Program for Islamic Architecture Thirtieth Anniversary Special Volume. BRILL. p. 324. .
Şehzade Kasım (1615/16,Tezcan , Baki: The Debut of Kösem Sultan's Career pp 354; HASANBEYZADE, Hasan Bey-zâde Târîhi, op. cit., vol. 3, p. 899; KARAÇELEBIZADE, Ravzatü’l-ebrâr, op. cit., p. 534 Constantinople – executed by order of Murad IV, 17 February 1638, Constantinople, Topkapı Palace, buried in Murad III Mausoleum, Hagia Sophia Mosque) - with Kösem Sultan;
Ibrahim I (13 October 1617,Tezcan , Baki: The Debut of Kösem Sultan's Career pp 354; fn 43: Mehmed ŞEYHI, Vakâyi'ü’l-fudalâ, 2 vols., Beyazıt Kütüphanesi, MS Veliyüddin Efendi 2361-2362; facs. ed., Abdülkadir ÖZCAN, Şakaik-ı Nu'maniye ve Zeyilleri, 5 vols., Istanbul, Çagrı, 1989, vols. 3-4, vol. 3, p. 150, gives an exact date as 12 Şevvâl 1026 / 13 October 1617 Constantinople – 18 August 1648, Constantinople, Topkapı Palace, murdered by janissaries and buried in Ibrahim I Mausoleum, Hagia Sophia Mosque) - with Kösem Sultan. 18th Sultan of the Ottoman Empire. |
Ahmed I | Daughters | Daughters
Ahmed I had at least eleven daughters:
Fülane Sultan (Early 1605, Constantinople-?) - She was born between the births of her half-brothers Osman and Mehmed. According to Venetian Bailo, Ottovaino Bon's report, her mother was another concubine whose name is not known- a woman other than Mahfiruz and Kösem.Tezcan, Baki: THE DEBUT OF KÖSEM SULTAN’S POLITICAL CAREER; “Non ha la Maestà Sua sposata alcuna schiava fin hora, et si ritrova haver con tredonne quattro figli, due maschi et due femine. Il maggiore, destinato alla successione, haverà cinque anni forniti;” the relation of Ottaviano Bon, read to the Venetian Senate on June 9, 1609, in Maria Pia PEDANI-FABRIS, ed., Relazioni di ambasciatori veneti al senato, vol. 14: Constantinopoli, Relazioni inedite (1512-1789) (Padova: Bottega d’Erasmo,1996), p. 475-523, at p. 514. She was the oldest daughter of Ahmed I and she was maybe married around 1610.
Ayşe Sultan (1606,Ayşe and her sister, Fatma were born- one around 1606 immediate to their elder brother, Mehmed and one by late 1608 or early 1609, but historians are uncertain about assigning dates. Ayşe is generally considered older than Fatma according to the Harem records which list residents in accordance with seniority. Constantinople – 1657, Constantinople, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque) - with Kösem Sultan,
Gevherhan Sultan (Late 1608, Constantinople – 1660, Constantinople, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque). She was named in honour of Ahmed's great aunt, Gevherhan Sultan who had gifted Ahmed's mother, Handan Sultan to his father, Mehmed III. Earlier she was presumed to have been Kösem's daughterPeirce, Leslie P. (1993), The Imperial Harem: Women and Sovereignty in the Ottoman Empire, Oxford University Press, p. 365, , however this is an inauthentic claim as Hanzade was determinably one of Kosem's three daughters instead and Gevherhan is now established Osman's full-sister and her marriage in 1612 to Öküz Mehmed Pasha worked as a political leverage for Osman, as the Pasha became Grand Vizier following the execution of Kösem's son-in-law, Nasuh Pasha in 1614 on the orders of Ahmed I.Tezcan, Baki; The Debut of Kösem Sultan's Career; pp 356
Fatma Sultan (Late 1608,“Non ha la Maestà Sua sposata alcuna schiava fin hora, et si ritrova haver con tredonne quattro figli, due maschi et due femine. Il maggiore, destinato alla successione,haverà cinque anni forniti;” the relation of Ottaviano Bon, read to the Venetian Senate on June 9, 1609, in Maria Pia PEDANI-FABRIS, ed., Relazioni di ambasciatori veneti al senato, vol. 14: Constantinopoli, Relazioni inedite (1512-1789) (Padova: Bottega d’Erasmo, 1996), p. 475-523, at p. 514., Constantinople – 1667, Constantinople, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque) - She was born of Kösem Sultan after the Venetian ambassador, Ottaviano Bon's report of June, 1609 detailing only 2 daughters from 2 different mothers- as the ambassador, Ottaviano read the report in June 1609, the information it reproduces may have been somewhat dated as he had left Istanbul earlier.Tezcan, Baki: THE DEBUT OF KÖSEM SULTAN’S POLITICAL CAREERand her mother was Kösem Sultan;
Hatice Sultan (post 1608, Constantinople – 1610, Constantinople, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque)-
Hanzade Sultan (1610/11, Constantinople – 21 September 1650, Constantinople, buried in Ibrahim I Mausoleum, Hagia Sophia Mosque) - She is generally considered the youngest of the three daughters of Ahmed I with Kösem Sultan and was definitely born after 1608 as the Venetian Bailo Ottovaino Bon's report was delivered June 1609 mentioned only 2 sons and 2 daughters of Ahmed I by three different women, i.e. only the two oldest surviving daughters of Ahmed I, Gevherhan with an unknown concubine and Ayşe with Kösem are mentioned. With her second full older sister, Fatma's birth estimated to have been around late 1608 or early 1609, she must've been born circa 1610 or early 1611 at the latest definitely before her younger full brother, Murad IV who was born on July 27, 1612.“Non ha la Maestà Sua sposata alcuna schiava fin hora, et si ritrova haver con tredonne quattro figli, due maschi et due femine. Il maggiore, destinato alla successione,haverà cinque anni forniti;” the relation of Ottaviano Bon, read to the Venetian Senate on June 9, 1609, in Maria Pia PEDANI-FABRIS, ed., Relazioni di ambasciatori veneti al senato, vol. 14: Constantinopoli, Relazioni inedite (1512-1789) (Padova: Bottega d’Erasmo, 1996), p. 475-523, at p. 514.
Esma Sultan (Constantinople, 1612 – Constantinople, 1612, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque)
Zahide Sultan (Constantinople, 1613 – Constantinople, 1620, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque)
Burnaz Atike Sultan ( 1614/1616?, Constantinople – 1674, Constantinople, buried in Ibrahim I Mausoleum, Hagia Sophia Mosque). She trained the future Valide Sultan, Turhan before presenting her to her half-brother, Ibrahim I- Turhan later rivalled and prevailed against Kösem Sultan.Dumas, Juliette; Les perles de nacre du sultanat; Pg 345: "...la reine mère Turhan Hadice Sultane avait été formée par Atike Sultane avant d’être offerte au sultan. La collusion entre la maison impériale et les maisons princières se repère jusque dans les échanges de femmes esclaves..."
Zeynep Sultan (Constantinople, 1617 – Constantinople, 1619, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque)
Ümmühan Sultan (ante 1616- after 1688) - She married Shehit Ali Pasha.
Abide Sultan (Constantinople, 1618 – Constantinople, 1648, buried in Ahmed I Mausoleum, Sultan Ahmed Mosque). Called also Übeyde Sultan, married in 1642 to Koca Musa Pasha (died in 1647) |
Ahmed I | Legacy | Legacy
Today, Ahmed I is remembered mainly for the construction of the Sultan Ahmed Mosque (also known as the Blue Mosque), one of the masterpieces of Islamic architecture. The area in Fatih around the Mosque is today called Sultanahmet. He died at Topkapı Palace in Constantinople and is buried in a mausoleum right outside the walls of the famous mosque. |
Ahmed I | In popular culture | In popular culture
In the 2015 TV series Muhteşem Yüzyıl: Kösem, Ahmed I is portrayed by Turkish actor Ekin Koç. |
Ahmed I | See also | See also
Transformation of the Ottoman Empire
Abbas I's Kakhetian and Kartlian campaigns |
Ahmed I | References | References |
Ahmed I | External links | External links
[aged 27]
Category:1590 births
Category:1617 deaths
Category:Deaths from typhus
Category:Child monarchs
Category:Ottoman people of the Ottoman–Persian Wars
Category:17th-century sultans of the Ottoman Empire
Category:Turks from the Ottoman Empire
Category:People from the Ottoman Empire of Bosnian descent
Category:Sons of sultans |
Ahmed I | Table of Content | Short description, Early life, Reign, Relations with Morocco, Ottoman-Safavid War: 1604–06, War with the Habsburgs: 1604–06, Jelali revolts, Ottoman-Safavid War: Peace and continuation, Capitulations and trade treaties, Architect and service to Islam, Character, Death, Family, Consorts, Sons, Daughters, Legacy, In popular culture, See also, References, External links |
Ahmed II | Short description | Ahmed II (; ; 25 February 1643 or 1 August 1642 – 6 February 1695) was the sultan of the Ottoman Empire from 1691 to 1695. |
Ahmed II | Early life | Early life
Ahmed II was born on 25 February 1643 or 1 August 1642, the son of Sultan Ibrahim and Muazzez Sultan. On 21 October 1649, Ahmed, along with his brothers Mehmed and Suleiman was circumcised.
During the reigns of his older brothers, Ahmed was imprisoned in Kafes, and he stayed there almost 43 years.
thumb|262px|The mausoleum of Ahmed II is located inside the türbe of Suleiman the Magnificent. (In the above picture, his tomb is seen side by side with Suleiman II and Suleiman the Magnificent). |
Ahmed II | Reign | Reign
During his reign, Ahmed II devoted most of his attention to the wars against the Habsburgs and related foreign policy, governmental and economic issues. Of these, the most important were the tax reforms and the introduction of the lifelong tax farm system (malikâne). Following the recovery of Belgrade under his predecessor, Suleiman II, the military frontier reached a rough stalemate on the Danube, with the Habsburgs no longer able to advance south of it, and the Ottomans attempting, ultimately unsuccessfully, to regain the initiative north of it.
Among the most important features of Ahmed's reign was his reliance on Köprülüzade Fazıl Mustafa Pasha. Following his accession to the throne, Ahmed II confirmed Fazıl Mustafa Pasha in his office as grand vizier. In office from 1689, Fazıl Mustafa Pasha was from the Köprülü family of grand viziers, and like most of his Köprülü predecessors in the same office, was an able administrator and military commander. Like his father Köprülü Mehmed Pasha (grand vizier, 1656–61) before him, Fazıl Mustafa Pasha ordered the removal and execution of dozens of corrupt state officials of the previous regime and replaced them with men loyal to himself. He overhauled the tax system by adjusting it to the capabilities of the taxpayers affected by the latest wars. He also reformed troop mobilization and increased the pool of conscripts available for the army by drafting tribesmen in the Balkans and Anatolia. In October 1690, Fazıl Mustafa Pasha recaptured Belgrade, a key fortress that commanded the confluence of the rivers Danube and Sava; in Ottoman hands since 1521, the fortress had been conquered by the Habsburgs in 1688.
Fazıl Mustafa Pasha's victory at Belgrade was a major military achievement that gave the Ottomans hope that the military debacles of the 1680s—which had led to the loss of Hungary and Transylvania, an Ottoman vassal principality ruled by pro-Istanbul Hungarian princes—could be reversed. However, the Ottoman success proved ephemeral. On 19 August 1691, Fazıl Mustafa Pasha suffered a devastating defeat at the Battle of Slankamen at the hands of Louis William, the Habsburg commander in chief in Hungary, nicknamed “Türkenlouis” (Louis the Turk) for his victories against the Ottomans. In the confrontation, recognized by contemporaries as “the bloodiest battle of the century,” the Ottomans suffered heavy losses: 20,000 men, including the grand vizier. With him, the sultan lost his most capable military commander and the last member of the Köprülü family, who for the previous half century had been instrumental in strengthening the Ottoman military.
Under Fazıl Mustafa Pasha's successors, the Ottomans suffered further defeats. In June 1692 the Habsburgs conquered Oradea, the seat of an Ottoman governor () since 1660. In 1694, they attempted to recapture Oradea, but to no avail. On 12 January 1695, they surrendered the fortress of Gyula, the center of an Ottoman sanjak (subprovince) since 1566. With the fall of Gyula, the only territory still in Ottoman hands in Hungary was to the east of the River Tisza and to the south of the river Maros, with its center at Timișoara. Three weeks later, on 6 February 1695, Ahmed II died in Edirne Palace. |
Ahmed II | Family | Family |
Ahmed II | Consorts | Consorts
Ahmed II had two known consorts:
Rabia Sultan (died Eski Palace, Istanbul, 14 January 1712, buried in Suleiman I Mausoleum, Süleymaniye Mosque). Ahmed II's most beloved consort and the last haseki sultan of the Ottoman Empire;
Şayeste Hatun (died in 1710). Second concubine of Ahmed II, perhaps mother of his other daughters. |
Ahmed II | Sons | Sons
Ahmed II had two sons:
Şehzade Ibrahim (Edirne Palace, Edirne, 6 October 1692 – Topkapı Palace, Istanbul, 4 May 1714, buried in Mustafa I Mausoleum, Hagia Sophia), with Rabia Sultan, Selim's twin, became crown prince on 22 August 1703 until his death;
Şehzade Selim (Edirne Palace, Edirne, 6 October 1692 – Edirne Palace, Edirne, 15 May 1693, buried in Sultan Mustafa Mausoleum, Hagia Sophia), with Rabia Sultan, he was Ibrahim's twin. |
Ahmed II | Daughters | Daughters
Ahmed II had three daughters:
Asiye Sultan (Edirne Palace, Edirne, 24 August 1694 – Eski Palace, Bayezid, Istanbul, 9 December 1695, buried in Suleiman I Mausoleum, Süleymaniye Mosque), with Rabia Sultan;
Atike Sultan (born 21 October 1694), probably with Şayeste Hatun. Died in infancy.
Hatice Sultan, probably with Şayeste Hatun. Died in infancy.
In addition to his daughters, Ahmed II was deeply attached to his niece Ümmügülsüm Sultan, daughter of his half-brother Mehmed IV, so much so that he treated her as if she were his own daughter. |
Ahmed II | References | References |
Ahmed II | Citations | Citations |
Ahmed II | Sources | Sources |
Ahmed II | Further reading | Further reading
Michael Hochendlinger, Austria's Wars of Emergence: War, State and Society in the Habsburg Monarchy, 1683–1797 (London: Longman, 2003), 157–64. |
Ahmed II | External links | External links
Category:1640s births
Category:1695 deaths
Category:Ottoman people of the Great Turkish War
Category:17th-century sultans of the Ottoman Empire
Category:Turks from the Ottoman Empire
Category:Sons of sultans |
Ahmed II | Table of Content | Short description, Early life, Reign, Family, Consorts, Sons, Daughters, References, Citations, Sources, Further reading, External links |
Ahmed III | Short description | alt=Sultan|thumb|Sultan Ahmed III
Ahmed III (, Aḥmed-i sālis; 30 December 16731 July 1736) was sultan of the Ottoman Empire and a son of sultan Mehmed IV (r. 1648–1687). His mother was Gülnuş Sultan, originally named Evmania Voria, who was an ethnic Greek. He was born at Hacıoğlu Pazarcık, in Dobruja. He succeeded to the throne in 1703 on the abdication of his brother Mustafa II (1695–1703). Nevşehirli Damat İbrahim Pasha and the Sultan's daughter, Fatma Sultan (wife of the former) directed the government from 1718 to 1730, a period referred to as the Tulip Era.
During the initial days of Ahmed III's reign, significant efforts were made to appease the janissaries. However, Ahmed's effectiveness in dealing with the janissaries who had elevated him to the sultanate was limited. Grand Vizier Çorlulu Ali Pasha, whom Ahmed appointed, provided valuable assistance in administrative affairs and implemented new measures for the treasury. He supported Ahmed in his struggles against rival factions and provided stability to the government. Ahmed was an avid reader, skilled in calligraphy and knowledgeable on history and poetry. |
Ahmed III | Early life and education | Early life and education
Sultan Ahmed was born on 30 December 1673. His father was Sultan Mehmed IV, and his mother was Gülnuş Sultan, originally named Evmenia. His birth occurred in Hacıoğlupazarı, where Mehmed stayed to hunt on his return from Poland in 1673, while Gülnuş was pregnant at that time. In 1675, He and his brother, Prince Mustafa (future Mustafa II) were circumcised. During the same ceremony their sisters Hatice Sultan and Fatma Sultan were married to Musahip Mustafa Pasha and Kara Mustafa Pasha respectively. The celebrations lasted 20 days.
He grew up in the Edirne Palace. His schooling began during one of the sporadic visits of the court to Istanbul, following a courtly ceremony called bad-i basmala, which took place on 9 August 1679 in the Istavroz Palace. He was brought up in the imperial harem in Edirne with a traditional princely education, studying the Qur’an, the hadiths (traditions of Muhammad), and the fundamentals of Islamic sciences, history, poetry and music under the supervision of private tutors. One of his tutors was chief mufti Feyzullah Efendi.
Ahmed was apparently curious and intellectual in nature, spending most of his time reading and practising calligraphy. The poems that he wrote manifest his profound knowledge of poetry, history, Islamic theology and philosophy. He was also interested in calligraphy, which he had studied with the leading court calligraphers, primarily with Hafız Osman Efendi (died 1698), who influenced his art immensely, and, therefore, practiced it because of the influence of his elder brother, the future Sultan Mustafa II, who also became a notable calligrapher.
During his princehood in Edirne, Ahmed made friends with a bright officer-scribe, Ibrahim, from the city of Nevşehir, who was to become one of the outstanding Grand Viziers of his future reign. From 1687, following the deposition of his father, he lived in isolation for sixteen years in the palaces of Edirne and Istanbul. During this period he dedicated himself to calligraphy and intellectual activities. |
Ahmed III | Reign | Reign |
Ahmed III | Accession | Accession
left|thumb|Ahmed III is proclaimed sultan and prepares to gird the sword of Osman
The Edirne succession occurred between 19 August to 23 August. Under Mustafa, Istanbul had been out of control for a long time. As arrests and executions mounted, theft and robbery incidents became common. The people were dissatisfied with the poor governing of the Empire. Mustafa was deposed by the Janissaries and Ahmed, who succeeded him to the throne on 22 August 1703. The first Friday salute was held in Bayezid Mosque.Sakaoğlu, Necdet (2015) Bu mülkün sultanları
Fındıklılı Mehmed Ağa welcomed the new sultan at the Harem gate on the Hasoda side, entered the arm, brought him to the Cardigan-i Saadet Department and placed them on the throne, and were among the first to pay tribute to him.
As part of the fief system, Ahmed reorganized the land law in 1705. Bringing order to land ownership reduced the crime wave and brought peace to the troubled Empire. Due to his ardent support of the new laws, Ahmed was given the title 'law-giver', a title given to only three sultans earlier, Bayezid II (r. 1481–1512), Selim I (r. 1512–1520) and Suleiman I (r. 1520–1566). In the first three years of his reign, Ahmed appointed four separate Grand Viziers. However, the government only gained some stability after the appointment of Çorlulu Ali Pasha in May 1706. |
Ahmed III | Russo-Turkish War of 1710–1711 | Russo-Turkish War of 1710–1711
Ahmed III cultivated good relations with France, doubtless in view of Russia's menacing attitude. He afforded refuge in Ottoman territory to Charles XII of Sweden (1682–1718) after the Swedish defeat at the hands of Peter I of Russia (1672–1725) in the Battle of Poltava of 1709. In 1710 Charles XII convinced Sultan Ahmed III to declare war against Russia, and the Ottoman forces under Baltacı Mehmet Pasha won a major victory at the Battle of Prut. In the aftermath, Russia returned Azov back to the Ottomans, agreed to demolish the fortress of Taganrog and others in the area, and to stop interfering in the affairs of the Polish–Lithuanian Commonwealth.
Forced against his will into war with Russia, Ahmed III came nearer than any Ottoman sovereign before or since to breaking the power of his northern rival, whose armies his grand vizier Nevşehirli Damat İbrahim Pasha succeeded in completely surrounding at the Pruth River Campaign in 1711. The subsequent Ottoman victories against Russia enabled the Ottoman Empire to advance to Moscow, had the Sultan wished. However, this was halted as a report reached Istanbul that the Safavids were invading the Ottoman Empire, causing a period of panic, turning the Sultan's attention away from Russia. |
Ahmed III | Wars with Venice and Austria | Wars with Venice and Austria
thumb|220x220px|Ahmed III in the Imperial Darbar of Topkapi Palace.On 9 December 1714, war was declared on Venice, an army under Silahdar Damat Ali Pasha's command managed to recover the whole Morea (Peloponnese) from Venice through coordinated operations of the army and navy.
This success alarmed Austria and in April 1716, Emperor Charles VI provoked the Porte into a declaration of war. The unsuccessful battle, also commanded by Silahdar Ali Pasha, ended with the Treaty of Passarowitz, signed on 21 July 1718, according to which Belgrade, Banat, and Wallachia were ceded to Austria. This failure was a disappointment for Ahmed as the treaty led to Istanbul's economy suffering from increased inflation.
Nevşehirli Damat Ibrahim Pasha who was the second leading figure of the empire after Ahmed had joined the Morea campaign in 1715, and was appointed as the city of Nish's minister of finance the following year. This post helped him realize the downturn of the state's finances, which led him to avoid war as much as possible during his vizierate. Ibrahim Pasha's policy of peace suited Ahmed well since he had no wish to lead any military campaigns, in addition to the fact that his interest in art and culture made him reluctant to leave his Istanbul. |
Ahmed III | Character of Ahmed's rule | Character of Ahmed's rule
thumb|Sultan Ahmed III at a reception, painted in 1720|left|298x298px
While shooting competitions were held in Okmeydanı, Istanbul with the idea of increasing the morale of the soldiers and the people, a new warship was launched in Tersane-i Amire.
He tried three grand viziers at short intervals. Instead of Hasan Pasha, he appointed Kalaylikoz Ahmed Pasha on 24 September 1704, and Baltacı Mehmed Pasha on 25 December 1704.
In 1707, a conspiracy led by Eyüplü Ali Ağa was unearthed to bring the sultan off the throne. What resulted were that necks were ordered to be cut in front of the Bab-I-Hümayun.
Ahmed III left the finances of the Ottoman Empire in a flourishing condition, which had remarkably been obtained without excessive taxation or extortionate procedures. He was a cultivated patron of literature and art, and it was in his time that the first printing press was authorized to use either the Arabic or Turkish languages; it was set up in Istanbul, and operated by Ibrahim Muteferrika (while the printing press had been introduced to Constantinople in 1480, all published works before 1729 were in Greek, Armenian, or Hebrew).
It was in his reign that an important change in the government of the Danubian Principalities was introduced: previously, the Porte had appointed Hospodars, usually native Moldavian and Wallachian boyars, to administer those provinces; after the Russian campaign of 1711, during which Peter the Great found an ally in Moldavia Prince Dimitrie Cantemir, the Porte began overtly deputizing Phanariote Greeks in that region, and extended the system to Wallachia after Prince Stefan Cantacuzino established links with Prince Eugene of Savoy. The Phanariotes constituted a kind of Dhimmi nobility, which supplied the Porte with functionaries in many important departments of the state. |
Ahmed III | Foreign relations | Foreign relations
thumb|Sultan Ahmed III receives French ambassador Vicomte d'Andrezel at Topkapı Palace.
thumb|French ambassador Marquis de Bonnac being received by Sultan Ahmed III.
The ambassadors of Safavid Iran and the Archduchy of Austria were well received when they came from 1706 to 1707.
In the year 1712, the Mughal Emperor Jahandar Shah, a grandson of Aurangzeb, sent gifts to the Ottoman Sultan Ahmed III and referred to himself as the Ottoman Sultan's devoted admirer.
The Mughal Emperor Farrukhsiyar, another grandson of Aurangzeb, is also known to have sent a letter to the Ottomans but this time it was received by the Grand Vizier Nevşehirli Damad Ibrahim Pasha. The letter provided a graphic description of the efforts of the Mughal commander Syed Hassan Ali Khan Barha fighting against the Rajput and Maratha rebellion. |
Ahmed III | Deposition | Deposition
Sultan Ahmed III had become unpopular by reason of the excessive pomp and costly luxury in which he and his principal officers indulged; on 20 September 1730, a mutinous riot of seventeen Janissaries, led by the Albanian Patrona Halil, was aided by the citizens as well as the military until it swelled into an insurrection, this consequently led the Sultan to give up his throne.
Ahmed voluntarily led his nephew Mahmud I (1730–1754) to the seat of sovereignty and paid allegiance to him as Sultan of the Empire. He then retired to the Kafes previously occupied by Mahmud and died at Topkapı Palace after six years of confinement. |
Ahmed III | Architecture | Architecture
Ahmed III commissioned the building of water claps, fountains, park waterfalls and three libraries, one inside the Topkapı Palace, with the famous lines "Ahmed was a master in the writings on plates" which have survived. The “Basmala” at the Topkapi Palace apartment door with its plates in the Üsküdar Yeni Mosque are among them.
A library was built by Ahmed in 1724–1725 situated next to the tomb entrance of Turhan Sultan, the structure has stone-brick alternate meshed walls, is square-shaped and covered with a flattened dome with an octagonal rim, which is provided with pendentives. There are original pen works left in the pendentives and dome of the library. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.